http://formularyjournal.modernmedicine.com/formulary Formulary provides peer-reviewed clinical information and news and drug approval updates to assist pharmacy and therapeutics committee members with their drug management responsibilities. 2009-07-04T10:02:54Z http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Therapeutic-considerations-in-managing-multiple-my/ArticleStandard/Article/detail/608422?ref=25 This review highlights treatment guidelines, disease staging criteria, and new therapeutic approaches to MM, including an overview of supportive care and emerging pipeline agents. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608422/MultipleMyeloma_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tolvaptan-Samsca-Vasopressin-receptor-antagonist-a/ArticleStandard/Article/detail/608420?ref=25 New molecular entity: Tolvaptan (Samsca), a vasopressin receptor antagonist, was approved on May 19, 2009, for the treatment of clinically significant hypervolemic and euvolemic hyponatremia 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608420null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/ADHD-medications-may-be-linked-to-sudden-unexplain/ArticleStandard/Article/detail/608425?ref=25 A matched, case-control analysis demonstrated an association between the use of stimulant medications (used to treat attention-deficit/hyperactivity disorder [ADHD]) and sudden unexplained death in children and adolescents. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608425null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Elevated-CRP-alone-does-not-justify-statin-treatme/ArticleStandard/Article/detail/608626?ref=25 C-reactive protein (CRP) does not add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of two studies published in the July 1, 2009, issue of the Journal of the American Medical Association. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608626null REMOTE http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/360-Network--THE-GUIDE--July-1-2009/ArticleStandard/Article/detail/607538?ref=25 360 Network 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/607538null HTML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/607468?ref=25 Agents in late-stage development for the treatment of migraine and cluster headaches 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/607468null PDF http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-July-2009-bucindolol-botulinu/ArticleStandard/Article/detail/608418?ref=25 Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608418null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Zoledronic-acid-Reclast-Bisphosphonate-approved-fo/ArticleStandard/Article/detail/608417?ref=25 New indication: Zoledronic acid (Reclast), a bisphosphonate, was approved on May 29, 2009, for the prevention of osteoporosis in postmenopausal women 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608417null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tadalafil-Adcirca-Phosphodiesterase-type-5-inhibit/ArticleStandard/Article/detail/608421?ref=25 New indication: Tadalafil (Adcirca), a phosphodiesterase type 5 inhibitor, was approved on May 22, 2009, for the treatment of pulmonary arterial hypertension (WHO Group I) 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608421null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Milnacipran-A-serotonin-and-norepinephrine-reuptak/ArticleStandard/Article/detail/608419?ref=25 Milnacipran was recently approved by FDA for the management of fibromyalgia syndrome. Clinical trials have demonstrated that this agent may be a reasonable alternative or adjunct therapy for patients with fibromyalgia syndrome who are unable to tolerate first-line tricyclic antidepressant therapy. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608419null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-June-2009-Besivance-Taxus-Lib/ArticleStandard/Article/detail/608424?ref=25 Recent FDA approvals (through July 2009) related to Besivance, Taxus Liberte Atom Stent System, Risperdal Consta, Prograf, Zipsor, Sprycel, Axert, Caldolor, and Lamictal XR 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608424null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approval-July-2009/ArticleStandard/Article/detail/608423?ref=25 Generic drug approved by FDA (through July 2009): melphalan injection 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608423null XML http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/Formulary-Brand-Information/ArticleStandard/Article/detail/605362?ref=25 2009-06-22T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/262009/605362null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Trial-of-sunitinib-plus-paclitaxel-for-advanced-br/ArticleStandard/Article/detail/603359?ref=25 Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603359null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Inconsistent-communication-within-CPOE-poses-signi/ArticleStandard/Article/detail/603329?ref=25 A prospective study published in Archives of Internal Medicine demonstrated that despite standardization of data entry within the computerized provider order entry (CPOE) system in a specific healthcare facility, inconsistent communication in orders entered into the CPOE posed a significant safety risk. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603329null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Golimumab-associated-with-risk-of-serious-fungal-i/ArticleStandard/Article/detail/603354?ref=25 Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603354null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Dutasteride-reduces-prostate-cancer-incidence-in-m/ArticleStandard/Article/detail/603360?ref=25 Dutasteride reduces the risk of biopsy-detectable prostate cancer by approximately one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers, said Gerald L. Andriole, Jr, MD, at the American Urological Association (AUA) 2009 Annual Meeting. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603360null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Acid-suppressive-medications-associated-with-incre/ArticleStandard/Article/detail/603338?ref=25 A prospective pharmacoepidemiologic cohort study published in JAMA demonstrated that hospitalized patients treated with acid-suppressive medications were 30% more likely to develop hospital-acquired pneumonia than those who were not treated with acid-suppressive medications. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603338null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+Meetings/Immunotherapy-improves-survival-in-advanced-prosta/ArticleStandard/Article/detail/603353?ref=25 Sipuleucel-T represents the "first active immunotherapy to demonstrate improvement in overall survival for advanced prostate cancer," said David Penson, MD, MPH, who announced the results of a phase 3 study known as Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT), at the American Urological Association (AUA) 2009 Annual Meeting. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603353null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Propylthiouracil-associated-with-increased-risk-of/ArticleStandard/Article/detail/603358?ref=25 FDA has notified healthcare professionals that there is a risk of serious liver injury, including liver failure or death, with the use of propylthiouracil in both adult and pediatric patients. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603358null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Golimumab-Simponi-Anti-TNF-alpha-mAb-approved-for-/ArticleStandard/Article/detail/601853?ref=25 New biologic: Golimumab (Simponi), an anti-TNF-alpha mAb, was approved on April 24, 2009, for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601853null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Overview-of-depression-and-its-management-in-child/ArticleStandard/Article/detail/601858?ref=25 This review addresses the prevalence and management of major depressive disorder (MDD) in school-aged children and adolescents, including treatment guidelines and agents under investigation for this indication. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601858/PediatricDepression_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-June-2009/ArticleStandard/Article/detail/603718?ref=25 Depression and its management in children and adolescents; Focus on bucindolol; Drug Watch: Agents in late-stage development for the treatment of Alzheimer's disease and cognitive impairment 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/252009/603718null REMOTE http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/360-Network--THE-GUIDE--June-1-2009/ArticleStandard/Article/detail/600645?ref=25 360 Network 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/222009/600645null HTML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-June-2009-lucinactant-fenreti/ArticleStandard/Article/detail/601857?ref=25 Recent FDA action (through June 2009) related to lucinactant, fenretinide, fampridine-SR, HPN-100, vitespen, and prodarsan 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601857null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-June-2009-Avastin-Azor-Exforg/ArticleStandard/Article/detail/601859?ref=25 Recent FDA approvals (through June 2009) related to Avastin, Azor, Exforge HCT, Cycloset, ACTOplus met XR, Lamictal ODT, Dysport, and Creon 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601859null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/601646?ref=25 Agents in late stage development for the treatment of Alzheimer's disease and cognitive impairment 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601646null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bucindolol-A-beta-blocker-for-the-treatment-of-hea/ArticleStandard/Article/detail/601855?ref=25 Bucindolol, an investigational agent under FDA review for the treatment of HF, is a nonspecific beta-blocker with weak alpha-blocking properties that may or may not possess intrinsic sympathomimetic activity. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601855null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Certolizumab-pegol-Cimzia-Anti-TNF-alpha-mAb-appro/ArticleStandard/Article/detail/601856?ref=25 New indication: Certolizumab pegol (Cimzia), an anti-TNF-alpha mAb, was approved on May 13, 2009, for the treatment of rheumatoid arthritis 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601856null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-gains-resources-for-strengthening-product-safe/ArticleStandard/Article/detail/601852?ref=25 FDA is stepping up oversight and enforcement activity for medical products as part of its efforts to demonstrate a vigorous approach to ensuring food and drug safety. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601852null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Iloperidone-Fanapt-Psychotropic-agent-approved-for/ArticleStandard/Article/detail/601854?ref=25 New molecular entity: Iloperidone (Fanapt), a psychotropic agent, was approved on May 6, 2009, for the acute treatment of schizophrenia 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601854null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Boxed-warning-added-to-botulinum-toxin-labeling/ArticleStandard/Article/detail/598452?ref=25 FDA has notified the manufacturers of botulinum toxin type A (Botox and Botox Cosmetic, Allergan), botulinum toxin type B (Myobloc, Solstice Neurosciences), and abobotulinumtoxinA (Dysport, Medicis/Ipsen) that the product labels need strengthened warnings, as well as a boxed warning, regarding the risk of adverse events when the effects of the toxin spread beyond the injection site. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598452null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clinical-judgment-is-best-guide-in-determining-app/ArticleStandard/Article/detail/598441?ref=25 Good clinical pharmacy judgment is still the most useful tool in evaluating the prescription needs of seniors, according to speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida, but the pharmacy professionals still reviewed various criteria and methods that can assist in evaluating senior patients, particularly those with cardiovascular disease. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598441null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Boxed-warning-added-to-labeling-of-testosterone-ge/ArticleStandard/Article/detail/598514?ref=25 FDA is requiring that a boxed warning be added to the product labeling for 2 testosterone gel products (AndroGel 1%, Solvay; Testim 1%, Auxilium). This warning states that there is a risk of virilization in children and women who are inadvertently exposed to these products. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598514null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/New-warnings-added-to-erlotinib-label/ArticleStandard/Article/detail/598513?ref=25 OSI and Genentech have issued a Dear Healthcare Professional letter regarding new warnings added to the labeling for erlotinib (Tarceva). 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598513null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clinical-outcomes-with-prasugrel-not-affected-by-c/ArticleStandard/Article/detail/598436?ref=25 An analysis published in Circulation demonstrated that the pharmacokinetic, pharmacodynamic, and clinical outcomes of prasugrel treatment are not affected by common functional cytochrome P450 (CYP) genetic variants, whereas clopidogrel treatment is affected by these genetic polymorphisms. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598436null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Serious-ADRs-associated-with-psychotropic-use-in-c/ArticleStandard/Article/detail/598340?ref=25 Prescribing psychotropic medications for attention-deficit/hyperactivity disorder (ADHD) and other disorders in children is common around the world, even though serious adverse drug reactions (ADRs) have been reported with the use of these drugs, said speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598340null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Rivaroxaban-superior-to-enoxaparin-in-preventing-V/ArticleStandard/Article/detail/598333?ref=25 Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598333null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Warning-about-suicidal-thoughts-and-actions-added-/ArticleStandard/Article/detail/598451?ref=25 FDA announced that manufacturers of antiepileptic and anticonvulsant drugs must update product labeling to include a warning about an increased risk of suicidal thoughts or actions associated with these drugs. The manufacturers must also develop Medication Guides for patient use. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598451null HTML http://formularyjournal.modernmedicine.com/formulary/2008-Top-branded-drugs-by-total-prescriptions/ArticleStandard/Article/detail/598275?ref=25 Top 100 branded drugs by total prescriptions 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598275null PDF http://formularyjournal.modernmedicine.com/formulary/Drug+and+Formulary+Management/2008-Top-branded-drugs-by-total-prescriptions-and-/ArticleStandard/Article/detail/598280?ref=25 2008 Top 100 branded drugs by total prescriptions and total retail dollars 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598280null HTML http://formularyjournal.modernmedicine.com/formulary/2008-Top-branded-drugs-by-total-retail-dollars/ArticleStandard/Article/detail/598276?ref=25 2008 Top 100 branded drugs by total dollars spent 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598276null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Comparative-effectiveness-research-may-shape-treat/ArticleStandard/Article/detail/596637?ref=25 The economic stimulus package approved by Congress in February provides more than $1 billion to support research on competing medical treatments. Although a fairly minor piece of the larger $789 billion American Recovery and Reinvestment Act of 2009 (ARRA), the provision set off widespread reaction to the possibility that comparative study results may be used to limit coverage of more expensive medicines. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596637null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Everolimus-Afinitor-Antineoplastic-agent-approved-/ArticleStandard/Article/detail/596630?ref=25 New molecular entity: Everolimus (Afinitor), an antineoplastic agent, was approved on March 30, 2009, for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596630null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-May-2009-budesonideformoterol/ArticleStandard/Article/detail/596632?ref=25 Recent FDA action (through May 2009) related to budesonide/formoterol, sertindole, quetiapine, saxagliptin, bevacizumab, dronedarone, and ofatumumab 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596632null XML http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/360-Network--THE-GUIDE--May-1-2009/ArticleStandard/Article/detail/596467?ref=25 360 Network 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596467null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-May-2009-Coartem-Ixiaro-Lexap/ArticleStandard/Article/detail/596633?ref=25 Recent FDA approvals (through May 2009) related to Coartem, Ixiaro, Lexapro, Reclast, and Symbyax 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596633null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-May-2009/ArticleStandard/Article/detail/596634?ref=25 Generic drugs approved by FDA (through May 2009) including drospirenone and ethinyl estradiol, levalbuterol, and topiramate 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596634null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Health-help-4-u-Mobile-telephone-technologies-come/ArticleStandard/Article/detail/596629?ref=25 Because so many people nowadays seem to be using cell phones rather than computers and e-mail to stay in touch, telemedicine programs are taking note of this trend and beginning to rely more on mobile phone technology. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596629null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-May-2009/ArticleStandard/Article/detail/597579?ref=25 Osteoarthritis: A review of treatment options; Focus on liraglutide; Drug Watch: Agents in late-stage development for the treatment of cystic fibrosis 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/597579/MayCoverOsteo_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/597579null REMOTE http://formularyjournal.modernmedicine.com/formulary/Endocrinology/Liraglutide-A-human-GLP-1-analogue-for-the-treatme/ArticleStandard/Article/detail/596635?ref=25 Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently pending FDA approval for the treatment of type 2 diabetes. This agent mimics the actions of food-induced endogenous GLP-1 release, thus causing glucose-dependent increased insulin secretion, decreased glucagon secretion, and reduced appetite and gastric emptying. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596635null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/596457?ref=25 Agents in late-stage development for the treatment of cystic fibrosis. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596457null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Osteoarthritis-A-review-of-treatment-options/ArticleStandard/Article/detail/596636?ref=25 Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596636/Osteoarthritis_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tigecycline-Tygacil-Tetracycline-class-antibiotic-/ArticleStandard/Article/detail/596631?ref=25 New indication: Tigecycline (Tygacil), a tetracycline-class antibiotic, was approved on March 20, 2009, for the treatment of community-acquired bacterial pneumonia 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596631null XML http://formularyjournal.modernmedicine.com/formulary/Policy+News/Sebelius-confirmed-as-Secretary-of-HHS/ArticleStandard/Article/detail/595677?ref=25 Kansas Governor Kathleen Sebelius has been confirmed and sworn in as the next Secretary of the US Department of Health and Human Services (HHS). 2009-04-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/182009/595677null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Higher-bapineuzumab-dose-discontinued-in-AD-trials/ArticleStandard/Article/detail/593322?ref=25 In 2 ongoing phase 3 trials of bapineuzumab, the highest dosing regimen (2 mg/kg) will be discontinued because of safety concerns, according to Wyeth and Elan. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593322null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clopidogrel-plus-aspirin-decreases-stroke-risk-in-/ArticleStandard/Article/detail/593300?ref=25 Among patients with atrial fibrillation (AF) who are deemed unsuitable for warfarin treatment or who are unwilling to take it, clopidogrel plus aspirin is superior to aspirin alone in preventing vascular events, including strokes, said Stuart Connolly, MD, at the American College of Cardiology 58th Annual Scientific Session. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593300null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Esomeprazole-treatment-does-not-improve-poorly-con/ArticleStandard/Article/detail/593310?ref=25 A randomized, placebo-controlled, double-blind trial published in the New England Journal of Medicine demonstrated no beneficial effect of esomeprazole for the treatment of poorly controlled asthma, even in patients with documented gastroesophageal reflux. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593310null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Sunitinib-trial-for-advanced-breast-cancer-discont/ArticleStandard/Article/detail/593324?ref=25 Pfizer has announced that a phase 3 trial of sunitinib monotherapy for the treatment of advanced breast cancer (SUN 1107) is being discontinued because of a statistical assessment for futility. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593324null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/New-data-confirm-safety-of-drug-eluting-stents/ArticleStandard/Article/detail/593323?ref=25 Findings from a prospective randomized clinical trial and a "real-world" registry demonstrate no excess risk of stent thrombosis and fewer clinical events in patients who receive drug-eluting stents (DES) compared with those who receive bare metal stents (BMS), according to data presented at the American College of Cardiology 58th Annual Scientific Session. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593323null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/High-dose-statin-before-PCI-decreases-periprocedur/ArticleStandard/Article/detail/593307?ref=25 Loading or reloading with high-dose atorvastatin reduces the risk of periprocedural myocardial infarction (MI) and vascular events in patients undergoing elective percutaneous coronary intervention (PCI), according to data presented at the American College of Cardiology 58th Annual Scientific Session. 2009-04-21T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/162009/593307null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Genentech-voluntarily-withdraws-efalizumab-from-th/ArticleStandard/Article/detail/592716?ref=25 Genentech has announced that the company is voluntarily withdrawing efalizumab (Raptiva) from the marketplace because of continuing concerns about progressive multifocal leukoencephalopathy (PML). 2009-04-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/152009/592716null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Parenteral-medication-errors-common-in-ICUs/ArticleStandard/Article/detail/591540?ref=25 In a multinational prospective study published in the BMJ, investigators demonstrated that parenteral medication errors are common occurrences in intensive care units (ICUs), but the number of errors can be reduced through the use of error-reporting and electronic prescribing systems. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591540null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/590964?ref=25 Agents in late-stage development for the treatment of hospital-acquired pneumonia, Clostridium difficile-associated diarrhea, and complicated skin and skin-structure infections. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/590964null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-April-2009/ArticleStandard/Article/detail/591536?ref=25 Generic drugs approved by FDA (through April 2009) including malathion lotion, 0.5% 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591536null XML http://formularyjournal.modernmedicine.com/formulary/Complete-access-to-our-April-2009-issue/ArticleStandard/Article/detail/594183?ref=25 Nebulized albuterol versus levalbuterol in pediatric and adult patients; Focus on clevidipine; Drug Watch: Agents in late-stage development for the treatment of complicated infections 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/172009/594183/SABACover_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/172009/594183null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Nebulized-albuterol-versus-levalbuterol-in-pediatr/ArticleStandard/Article/detail/591538?ref=25 This article reviews the similarities and differences between albuterol (ALB) and levalbuterol (LEV) to provide P&T committees a concise summary of the available literature regarding efficacy, side effects, and cost of these agents. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591538/LevalbuterolVsAlbuterol_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-April-2009-alglucosidase-alfa/ArticleStandard/Article/detail/591535?ref=25 Recent FDA action (through April 2009) related to alglucosidase alfa, bosentan, cetuximab, doxepin, telavancin, quetiapine extended-release, oxycodone/niacin, and EUR-1073 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591535null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-April-2009-PegIntron-Rebetol-/ArticleStandard/Article/detail/591534?ref=25 Recent FDA approvals (through April 2009) related to PegIntron, Rebetol, Apidra SoloSTAR, Temodar, Copaxone, and Edluar 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591534null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Food-and-drug-safety-crises-prompt-White-House-con/ArticleStandard/Article/detail/591539?ref=25 The headlines about contaminated heparin and tainted peanuts have put pressure on FDA to improve its methods for detecting unsafe medical and food products and to take swift action when problems emerge. The complaints are prompting the Obama administration to provide more resources for FDA while Congress weighs expanding agency operations and enforcement authority. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591539null XML http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/360-Network--THE-GUIDE--April-1-2009/ArticleStandard/Article/detail/589960?ref=25 360 Network 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/589960null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Clevidipine-An-intravenous-dihydropyridine-calcium/ArticleStandard/Article/detail/591537?ref=25 Clevidipine is an intravenous (IV) dihydropyridine calcium-channel blocker (CCB) that is approved for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is effective at reducing BP in the emergency room (ER), intensive care unit (ICU), and in the pre-, peri-, and postoperative settings. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591537null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/BudesonideFormoterol-Symbicort-CorticosteroidLABA-/ArticleStandard/Article/detail/591533?ref=25 New indication: Budesonide/formoterol (Symbicort), a corticosteroid/LABA combination, was approved on February 27, 2009, for the maintenance treatment of COPD 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591533null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Modafinil-has-potential-for-abuse-and-addiction-be/ArticleStandard/Article/detail/591541?ref=25 In a pilot study published in the Journal of the American Medical Association, investigators demonstrated that modafinil blocks dopamine transporters and increases dopamine levels in the brain, suggesting that this agent has the potential for abuse and addiction. 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591541null XML http://formularyjournal.modernmedicine.com/formulary/Diabetes+and+Endocrinology/Labeling-updates-and-warnings-through-April-2009-f/ArticleStandard/Article/detail/591542?ref=25 Labeling updates and warnings through April 2009 for insulin pens and cartridges 2009-04-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/142009/591542null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/Bevasiranib-trial-for-wet-AMD-discontinued/ArticleStandard/Article/detail/586362?ref=25 OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD). 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586362null HTML http://formularyjournal.modernmedicine.com/formulary/Oncology/Elesclomol-trials-suspended-because-of-safety-conc/ArticleStandard/Article/detail/586370?ref=25 Synta Pharmaceuticals and GlaxoSmithKline have announced that they are suspending a phase 3 trial of elesclomol in chemotherapy-naïve patients with stage IV metastatic melanoma because of safety concerns. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586370null HTML http://formularyjournal.modernmedicine.com/formulary/Policy+News/Debate-over-follow-on-biologic-legislation-continu/ArticleStandard/Article/detail/586366?ref=25 At the 2009 annual meeting of the Generic Pharmaceutical Association (GPhA) in February, House Energy and Commerce Committee Chairman Henry Waxman told attendees that a workable scientific, regulatory, and legal pathway for follow-on biologics (also referred to as biogenerics or biosimilar pharmaceuticals) would lead to more affordable medications for Americans. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586366null HTML http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Boxed-warning-about-tardive-dyskinesia-added-to-me/ArticleStandard/Article/detail/586376?ref=25 FDA has stated that manufacturers of metoclopramide must add a boxed warning to their drug labels regarding the risk of tardive dyskinesia with long-term or high-dose use of this agent. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586376null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Few-hospitals-give-t-PA-to-patients-with-ischemic-/ArticleStandard/Article/detail/586398?ref=25 Two-thirds of US hospitals do not administer tissue plasminogen activator (t-PA) to patients who have a stroke and are covered by Medicare, according to the results of a national study conducted between 2005 and 2007, which were presented at the International Stroke Conference 2009. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586398null HTML http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Transdermal-medication-patches-may-lead-to-burns-d/ArticleStandard/Article/detail/586379?ref=25 FDA has issued a public health advisory regarding a risk of burns during magnetic resonance imaging (MRI) scans in patients wearing transdermal medication patches that contain aluminum or other metals in the backing of the patches. The patches can overheat during the scan, leading to skin burns in the area of the patch. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586379null HTML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/Maribavir-trial-for-CMV-prophylaxis-discontinued/ArticleStandard/Article/detail/586357?ref=25 ViroPharma has announced that it is discontinuing a phase 3 trial of maribavir for prophylaxis against cytomegalovirus (CMV) disease in patients undergoing a liver transplant. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586357null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clopidogrel-plus-PPI-after-hospitalization-for-ACS/ArticleStandard/Article/detail/586399?ref=25 A retrospective cohort study published in the Journal of the American Medical Association demonstrated that concomitant use of clopidogrel and a proton-pump inhibitor (PPI) after hospital discharge for acute coronary syndrome (ACS) is associated with an increased risk of all-cause mortality and rehospitalization for ACS. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586399null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Rosuvastatin-associated-with-significant-stroke-ri/ArticleStandard/Article/detail/586394?ref=25 Apparently healthy people with normal cholesterol levels but elevated levels of high-sensitivity C-reactive protein (hsCRP) demonstrated a significant relative reduction in stroke risk if treated with rosuvastatin rather than placebo in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, according to data presented at the International Stroke Conference 2009. 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586394null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Intraventricular-delivery-of-t-PA-improves-outcome/ArticleStandard/Article/detail/586364?ref=25 Catheter delivery of tissue plasminogen activator (t-PA) improves survival and functional outcomes at 6 months in patients with intraventricular hemorrhage (IVH), according to the final results from a phase 2b study known as Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR IVH). 2009-03-12T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112009/586364null HTML http://formularyjournal.modernmedicine.com/formulary/Policy+News/Supreme-Court-rules-against-Wyeth-in-Wyeth-v-Levin/ArticleStandard/Article/detail/584803?ref=25 In a decision handed down March 4, 2009, the U.S. Supreme Court ruled in favor of Levine in the court case Wyeth v Levine, upholding the ruling of the Vermont Supreme Court. This decision may set a precedent for rejecting the argument of pre-emption, a tenet holding that FDA regulations connected with drug approvals and medication safety supersede state laws. 2009-03-04T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584803null HTML http://formularyjournal.modernmedicine.com/formulary/Policy+News/Sebelius-nominated-for-secretary-of-HHS/ArticleStandard/Article/detail/584297?ref=25 In a news conference on March 2, President Obama nominated Kansas Governor Kathleen Sebelius to the post of secretary of Health and Human Services (HHS). He also nominated Nancy Ann DeParle to the post of director of the White House Office for Health Reform. 2009-03-02T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584297null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/Febuxostat-Uloric-Xanthine-oxidase-inhibitor-appro/ArticleStandard/Article/detail/584581?ref=25 Febuxostat (Uloric): Xanthine oxidase inhibitor approved for chronic management of hyperuricemia in patients with gout 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584581null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Anti-TNF-alpha-monoclonal-antibodies-associated-wi/ArticleStandard/Article/detail/584591?ref=25 In a study published in the Journal of the American Medical Association, investigators demonstrated an association between treatment with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibodies (mAbs) adalimumab and infliximab and risk of herpes zoster events in patients with rheumatoid arthritis (RA). 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584591null XML http://formularyjournal.modernmedicine.com/formulary/Complete-access-to-our-March-2009-issue/ArticleStandard/Article/detail/587840?ref=25 Review of common sexually transmitted diseases; Focus on ustekinumab; Drug Watch: Agents in late-stage development for the treatment of pulmonary diseases 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/122009/587840/MarchCoverSTDs_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/122009/587840null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Calcitriol-Vectical-Vitamin-D-analogue-approved-fo/ArticleStandard/Article/detail/584583?ref=25 New formulation: Calcitriol (Vectical), a Vitamin D analogue, was approved on January 23, 2009, for the treatment of mild-to-moderate plaque psoriasis 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584583null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-March-2009/ArticleStandard/Article/detail/584586?ref=25 Generic drugs approved by FDA (through March 2009) including sumatriptan tablets, divalproex extended-release tablets, and risperidone oral solution 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584586null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/A-review-of-common-sexually-transmitted-diseases/ArticleStandard/Article/detail/584588?ref=25 Although there have been significant advances in prevention, diagnosis, treatment, and education, the occurrence of sexually transmitted diseases (STDs) continues to increase. This article focuses on the diagnosis and treatment of the most common STDs. 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584588/MarchSTDs_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-March-2009-cetuximab-prasugre/ArticleStandard/Article/detail/584585?ref=25 Recent FDA action (through March 2009) related to cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, and omacetaxine 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584585null XML http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Labeling-updates-and-warnings-through-March-2009-f/ArticleStandard/Article/detail/584592?ref=25 Labeling updates and warnings through March 2009 for zonisamide and efalizumab 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584592null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-March-2009-Gelnique-RiaSTAP-K/ArticleStandard/Article/detail/584584?ref=25 Recent FDA approvals (through March 2009) related to Gelnique, RiaSTAP, and Kapidex 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584584null XML http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/360-Network--THE-GUIDE--March-1-2009/ArticleStandard/Article/detail/584176?ref=25 360 Network 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584176null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Healthcare-reformers-seek-greater-transparency-in-/ArticleStandard/Article/detail/584589?ref=25 A prominent theme in health-reform efforts is the need for more transparent information about healthcare cost and quality upon which providers and patients can base their treatment decisions. Many federal agencies and state governments are expanding their requirements for pharmaceutical companies to report payments made to researchers and physicians, and for health plans to give beneficiaries more information on drug costs and coverage. 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584589null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Antithrombin-recombinant-ATryn-Recombinant-human-a/ArticleStandard/Article/detail/584582?ref=25 New biologic: Antithrombin (recombinant) (ATryn), a recombinant human antithrombin, was approved on February 6, 2009, for the prevention of perioperative and peripartum thromboembolic events in hereditary antithrombin-deficient patients 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584582null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Ustekinumab-A-human-monoclonal-antibody-for-the-tr/ArticleStandard/Article/detail/584587?ref=25 Ustekinumab is a novel investigational human monoclonal antibody (mAb) that is pending approval for the treatment of plaque psoriasis. Subcutaneous administration of ustekinumab has demonstrated efficacy in both phase 2 and 3 trials. 2009-03-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/102009/584587null XML